{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.66","upperLimit":"6.44","value":"1.76"},{"groupId":"OG001","lowerLimit":"1.77","upperLimit":"1.87","value":"1.82"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Time to Response was defined in participants with best overall response of complete response or partial response as determined by Investigator. It is the interval from the date of the first dose to date of first documentation of tumor response that was subsequently confirmed by investigator assessment.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Adult participants (≥ 18 years) were administered Tovorafenib 600 mg orally (PO) once weekly (QW).","id":"OG000","title":"Melanoma Cohort"},{"description":"Adult participants (≥ 18 years) were administered Tovorafenib 600 mg PO QW.","id":"OG001","title":"Tissue Agnostic Cohort"}],"paramType":"MEDIAN","populationDescription":"Participants in the Efficacy Analysis Set who have a confirmed response of CR or PR were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 23 months","title":"Time to Response","type":"SECONDARY","unitOfMeasure":"Months"}